Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model

被引:12
作者
Yonezawa, Sei
Asai, Tomohiro
Oku, Naoto
机构
[1] Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, Suruga Ku, Shizuoka 4228526, Japan
[2] Univ Shizuoka, Sch Pharmaceut Sci, COE Program Century 21st, Suruga Ku, Shizuoka 4228526, Japan
关键词
anti-neovascular therapy; liposome; pancreatic cancer; angiogenesis; GROWTH; BEVACIZUMAB; TRIAL;
D O I
10.1016/j.jconrel.2006.12.024
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Pancreatic cancer is one of the most serious cancers with poor therapeutic results and prognosis. In here, we proposed a novel treatment strategy of pancreatic cancer by injuring limited angiogenic vessels with liposome containing adriamycin. At first, we established an orthotopic tumor model, which has a hypovascular characteristic of pancreatic tumor. In this model, we obtained the enhanced therapeutic efficacy with liposome that modified by polyethylene glycol (PEG) and a peptide, Ala-Pro-Arg-Pro-Gly (APRPG), having an affinity to neovessels. Histochemical analysis suggested the degradation of angiogenic vessels after treatment with APRPG-PEG-liposomal adriamycin. In addition, we observed colocalization of fluorescence-labeled APRPG-PEG-liposome with angiogenic endothelial cells, although the biodistribution of H-3-labeled liposome did not show the difference in the amount of accumulation between PEG-modified liposome and APRPG-PEG-i-nodified liposome. These results suggested the availability of the anti-neovascular therapy against pancreatic cancer and supply a new sight indication on chemotherapeutics against pancreatic cancer. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 21 条
[11]   Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review [J].
Maeda, H ;
Wu, J ;
Sawa, T ;
Matsumura, Y ;
Hori, K .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :271-284
[12]   Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome [J].
Maeda, N ;
Takeuchi, Y ;
Takada, M ;
Sadzuka, Y ;
Namba, Y ;
Oku, N .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :41-52
[13]   Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate [J].
Maeda, N ;
Takeuchi, Y ;
Takada, M ;
Namba, Y ;
Oku, N .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (04) :1015-1017
[14]   Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs [J].
Maeda, Noriyuki ;
Miyazawa, Souichiro ;
Shimizu, Kosuke ;
Asai, Tomohiro ;
Yonezawa, Sei ;
Kitazawa, Sadaya ;
Namba, Yukihiro ;
Tsukada, Hideo ;
Oku, Naoto .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (09) :1936-1940
[15]  
Martin D R, 2000, Magn Reson Imaging Clin N Am, V8, P787
[16]   Anti-neovascular therapy using novel peptides homing to angiogenic vessels [J].
Oku, N ;
Asai, T ;
Watanabe, K ;
Kuromi, K ;
Nagatsuka, M ;
Kurohane, K ;
Kikkawa, H ;
Ogino, K ;
Tanaka, M ;
Ishikawa, D ;
Tsukada, H ;
Momose, M ;
Nakayama, J ;
Taki, T .
ONCOGENE, 2002, 21 (17) :2662-2669
[17]   Anticancer therapy using glucuronate modified long-circulating liposomes [J].
Oku, N .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 40 (1-2) :63-73
[18]  
ROSAI J, 1996, ACKERMANS SURG PATHO, P969
[19]   Angiocytotoxic therapy in human non-small cell lung cancer cell lines -: Advantage of combined effects of TNP-470 and SN-38 [J].
Satoh, H ;
Ishikawa, H ;
Fujimoto, M ;
Fujiwara, M ;
Yamashita, YT ;
Yazawa, T ;
Ohtsuka, M ;
Hasegawa, S ;
Kamma, H .
ACTA ONCOLOGICA, 1998, 37 (01) :85-90
[20]  
SEMELKA RC, 2002, ABDOMINAL PELVIC MRI, P373